The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large internat...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Adv
Main Authors: Stahl, Maximilian, DeVeaux, Michelle, de Witte, Theo, Neukirchen, Judith, Sekeres, Mikkael A., Brunner, Andrew M., Roboz, Gail J., Steensma, David P., Bhatt, Vijaya R., Platzbecker, Uwe, Cluzeau, Thomas, Prata, Pedro H., Itzykson, Raphaël, Fenaux, Pierre, Fathi, Amir T., Smith, Alexandra, Germing, Ulrich, Ritchie, Ellen K., Verma, Vivek, Nazha, Aziz, Maciejewski, Jaroslaw P., Podoltsev, Nikolai A., Prebet, Thomas, Santini, Valeria, Gore, Steven D., Komrokji, Rami S., Zeidan, Amer M.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2018
נושאים:
Myeloid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058241/
https://ncbi.nlm.nih.gov/pubmed/30037803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019414
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים